The rare autoimmune disease drug Tavneos (Avacopan) has been recalled across multiple jurisdictions following international safety signals, including reports of 20 patient deaths in Japan. According to the Health Products Regulatory Authority, distribution of the treatment from Irish wholesalers ceased on 11 August, with a formal recall of remaining wholesale stock requested on Thursday.
Regulatory Actions Across Europe and Japan
Regulatory bodies across Europe and Asia have moved swiftly to pull the medication following safety reviews. According to Kissei Pharmaceutical, which holds commercial rights for the treatment in Japan, 20 deaths were reported among a cohort of more than 8,500 patients treated with the medication in the country since 2022. Kissei subsequently warned prescribing physicians about the risk of severe liver dysfunction.
At the European level, the European Medicines Agency warned in June that the benefits of the medication were no longer proven to outweigh its risks. Following a data reassessment, the agency recommended in July that Tavneos be stripped of its market authorisation, a decision officially endorsed by the European Commission earlier this month. In France, the national medicine safety agency ANSM announced that a full batch recall would begin on 19 August, mirroring actions taken in the Republic of Ireland by the Health Products Regulatory Authority.
Impact on Patients and Clinical Guidance in Ireland
Prior to the European regulatory intervention, approximately 60 patients were actively treated with Tavneos in the Republic of Ireland, according to figures reported by Irish broadcaster RTÉ. The medication, manufactured by US biotech firm Amgen and distributed through various global partners, is indicated for adults suffering from severe, rare autoimmune conditions that trigger blood vessel inflammation, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
The Health Products Regulatory Authority noted that the drug was strictly prescribed by medical consultants possessing specialist experience in managing these complex conditions. Regulators emphasized that some specialists had already transitioned patients away from the therapy. Patients currently prescribed Tavneos have been explicitly advised by health authorities not to halt their treatment regimen without first consulting their attending physicians.
Did You Know?
Global Regulatory Divergence
Regulatory approaches to the safety signals vary significantly by region. While European regulators and the Health Products Regulatory Authority moved to strip authorizations and pull stock, the United States Food and Drug Administration took a different route. According to reporting from RTÉ, the Food and Drug Administration offered Amgen the option of a voluntary withdrawal. Following the company’s refusal, a formal procedure was initiated to determine whether federal regulators will force a market removal.
Meanwhile, the Medicines and Healthcare products Regulatory Agency in the United Kingdom announced in June that it was actively reviewing the benefit-risk profile of the drug. Further updates from the United Kingdom regulator are pending.
Frequently Asked Questions
Why was Tavneos recalled?
The recall follows safety concerns and reports of 20 patient deaths in Japan, leading the European Medicines Agency to conclude that the drug’s benefits no longer outweigh its risks.
What should patients currently taking Tavneos do?
According to the Health Products Regulatory Authority, patients must not stop taking the medication without first consulting their doctor or specialist consultant.
Who manufactures Tavneos?
Tavneos (Avacopan) is manufactured by the US biotech firm Amgen and distributed globally through various pharmaceutical partners, including Kissei Pharmaceutical in Japan.
How many patients were affected in Ireland?
According to RTÉ, approximately 60 individuals were receiving treatment with the drug in the Republic of Ireland before the European Medicines Agency issued its restriction recommendation.
Stay informed on critical health updates and pharmaceutical recalls by subscribing to our daily newsletter or exploring our latest news coverage.